Poland· PL-100425937
Apropol
A opipramol product containing opipramoli dihydrochloridum, registered in Poland by Polfarmex S.A.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Opipramol is registered in 5 of 19 countries.
Countries holding a registration under ATC N06AA05 (opipramol), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Opipramol · ATC N06AA05
5 / 19 countries
- Finlandprice
- Germany
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Opipramoli dihydrochloridum
- Manufacturer
- Polfarmex S.A.
- Country
- Poland (PL)
- ATC code
- N06AA05
- ATC class
- Opipramol
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991523879
- gtin05909991523886
- gtin05909991523893
- gtin05909991523909
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
36 interactions on record for opipramol.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Opipramol · interactions on record
36 records
36 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Opipramol in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- GermanyInsidonLaboratoires Juvise Pharmaceuticals
- SwitzerlandInsidon, DragéesMedius AG
- NorwayInsidonUkjent (2)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Austria · Insidon
- Germany · Insidon, Ophel
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c847a039-41eb-4f57-b747-99b8dd9b2c29 GET /v1/drugs/c847a039-41eb-4f57-b747-99b8dd9b2c29?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg",
"packaging": "05909991523879 ¦ Rp ¦ 151711\n56 tabl.\n05909991523886 ¦ Rp ¦ 151712\n90 tabl.\n05909991523893 ¦ Rp ¦ 151713\n60 tabl.\n05909991523909 ¦ Rp ¦ 151714\n20 tabl.",
"substance": "Opipramoli dihydrochloridum 50 mg",
"common_name": "Opipramoli dihydrochloridum",
"pl_product_id": "100425937",
"pozwolenie_nr": "28076",
"auth_procedure": "NAR",
"authorisation_validity": "2028-10-26"
}See everything about opipramol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.